We are delighted that our Head of Computational Biology and AI, Dr Namshik Han, was featured on Cytiva’s ‘Discovery Matters‘ podcast series last month.
Cytiva – a Milner affiliated company – use their podcast series to bring together experts from across the life sciences industry to deliver stories and insights on discoveries that advance life sciences. Their latest episode focuses on the potential of artificial intelligence (AI) and machine learning to revolutionize biomedical research and make personalized healthcare a reality. Namshik is joined on the podcast by Kourosh Saeb-Parsy, Professor of Transplantation at the University of Cambridge and CEO of Avatrial, a biomedical start-up company housed in the Milner Institute’s Bio-incubator, Frame Shift. Discussions throughout the episode include the significance of advanced technology for unlocking discoveries in transplantation research, precision medicine and more.
About Namshik’s research
The aim of the Milner Institute’s computational research and artificial intelligence team, led by Dr Namshik Han is to create an atlas of disease mechanisms through the integration and interrogation of large multi-omic datasets. The team are using bespoke machine learning methods to identify new signatures of disease and therapeutic targets, as well as network analysis to gain a deep understanding of the underlying causes of disease. The team have an established track record of collaboration with industry in the UK and Asia (e.g. GSK, AstraZeneca, Storm Therapeutics and JW Pharmaceutical) and drug discovery partners (e.g. LifeArc, Cancer Research Horizons and the CRUK Cambridge Centre). Through these collaborations they have developed and validated methodologies which have clear applications in drug discovery. The team works with closely with researchers and clinicians throughout Cambridge who have unique patient datasets and disease models, as well as academic institutions in the UK, USA and Asia (e.g. University of Liverpool, Yonsei University and the University of California, Irvine). It is this sharing of cross-sector expertise that ensures results are biologically interpretable and can inform go/no go decision making in drug discovery. The team’s approaches have been applied to target identification and drug repositioning and are applicable across many areas of healthcare including early detection and personalised medicine.
About Cytiva
Cytiva – a Milner affiliated company – is a global provider of technologies and services that advance and accelerate the development and manufacture of therapeutics. Cytiva’s mission is to advance and accelerate the development and manufacture of therapeutics. This is an exciting time as science is evolving and ushering in a new era of medicine. Biopharma companies and researchers are adapting to keep up with the pace of innovation and remain resilient in the midst of a changing global landscape. Cytiva provides the tools, technologies, solutions, and expertise to bring therapeutics from discovery to delivery.
